clinical trial · NCT04887298
Study of Liposomal Annamycin for the Treatment of Subjects with Soft-Tissue Sarcomas (STS) with Pulmonary Metastases
Sarcoma,Soft TissuePulmonary MetastasisLiposomal Annamycin (L-Annamycin)
brief summary
This is a multi-center, open-label, single-arm study that in Phase 1b will determine the maximum tolerated dose (MTD)/ recommended phase 2 dose (RP2D) and safety of L-Annamycin and in Phase 2 will explore the efficacy of L- Annamycin as a single agent for the treatment of subjects with STS with lung metastases for which chemotherapy is considered appropriate.
started
Jun 5, 2021
primary completion
Sep 29, 2022
completion
Aug 6, 2024
last updated
Oct 24, 2024
official title
Phase 1B/2 Study of Liposomal Annamycin (L-Annamycin) in Subjects with Previously Treated Soft-Tissue Sarcomas with Pulmonary Metastases
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol